Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease

Funda Korkmaz; Judit Gimenez-Roig; Farhath Sultana; Victoria Laurencin; Fasilet Sen; Liam Cullen; Steven Sims; Anusha Pallapati; Satish Rojekar; Guzel Burganova; Georgii Pevnev; Uliana Cheliadinova; Darya Vasilyeva; Ofer Moldavski; Tal Frolinger; Anisa Gumerova; Orly Barak; Vitaly Ryu; Daria Lizneva; Keqiang Ye; Anne Schafer; Clifford J. Rosen; Tony Yuen; Se Min Kim; Mone Zaidi

doi:10.1016/j.molmed.2025.05.001

Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease

Funda Korkmaz
, Judit Gimenez-Roig
, Farhath Sultana
, Victoria Laurencin
, Fasilet Sen
, Liam Cullen
, Steven Sims
, Anusha Pallapati
, Satish Rojekar
, Guzel Burganova
, Georgii Pevnev
, Uliana Cheliadinova
, Darya Vasilyeva
, Ofer Moldavski
, Tal Frolinger
, Anisa Gumerova
, Orly Barak
, Vitaly Ryu
, Daria Lizneva
, Keqiang Ye

Anne Schafer, Clifford J. Rosen, Tony Yuen, Se Min Kim, Mone Zaidi

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Follicle-stimulating hormone (FSH), traditionally known for regulating gonadal development, maturation, and estrogen secretion, has now been implicated in regulating fat and bone metabolism and cognition. Preclinical evidence from genetic and pharmacological studies in rodent models, combined with human data from population-based observations, genetic studies, and a limited number of interventional trials, supports the notion of independent effects of FSH on the skeleton, fat, and brain. This evolving understanding of the nonreproductive roles of FSH presents potential therapeutic opportunities to mitigate age-related health challenges, which include osteoporosis, obesity, cardiovascular risk, and dementia. This review summarizes the current knowledge on the interplay between pituitary-derived FSH and peripheral and central tissues, as well as recent progress in therapeutic development.

Original language	English
Pages (from-to)	1021-1031
Number of pages	11
Journal	Trends in Molecular Medicine
Volume	31
Issue number	11
DOIs	https://doi.org/10.1016/j.molmed.2025.05.001
State	Published - Nov 2025

Keywords

FSH
bone
brain
fat
pituitary

Access to Document

10.1016/j.molmed.2025.05.001

Cite this

Korkmaz, F., Gimenez-Roig, J., Sultana, F., Laurencin, V., Sen, F., Cullen, L., Sims, S., Pallapati, A., Rojekar, S., Burganova, G., Pevnev, G., Cheliadinova, U., Vasilyeva, D., Moldavski, O., Frolinger, T., Gumerova, A., Barak, O., Ryu, V., Lizneva, D., ... Zaidi, M. (2025). Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease. Trends in Molecular Medicine, 31(11), 1021-1031. https://doi.org/10.1016/j.molmed.2025.05.001

@article{ddaac704ec9e425bb04b4bb0912fd9d3,

title = "Targeting FSH for osteoporosis, obesity, and Alzheimer{\textquoteright}s disease",

abstract = "Follicle-stimulating hormone (FSH), traditionally known for regulating gonadal development, maturation, and estrogen secretion, has now been implicated in regulating fat and bone metabolism and cognition. Preclinical evidence from genetic and pharmacological studies in rodent models, combined with human data from population-based observations, genetic studies, and a limited number of interventional trials, supports the notion of independent effects of FSH on the skeleton, fat, and brain. This evolving understanding of the nonreproductive roles of FSH presents potential therapeutic opportunities to mitigate age-related health challenges, which include osteoporosis, obesity, cardiovascular risk, and dementia. This review summarizes the current knowledge on the interplay between pituitary-derived FSH and peripheral and central tissues, as well as recent progress in therapeutic development.",

keywords = "FSH, bone, brain, fat, pituitary",

author = "Funda Korkmaz and Judit Gimenez-Roig and Farhath Sultana and Victoria Laurencin and Fasilet Sen and Liam Cullen and Steven Sims and Anusha Pallapati and Satish Rojekar and Guzel Burganova and Georgii Pevnev and Uliana Cheliadinova and Darya Vasilyeva and Ofer Moldavski and Tal Frolinger and Anisa Gumerova and Orly Barak and Vitaly Ryu and Daria Lizneva and Keqiang Ye and Anne Schafer and Rosen, \{Clifford J.\} and Tony Yuen and Kim, \{Se Min\} and Mone Zaidi",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Ltd.",

year = "2025",

month = nov,

doi = "10.1016/j.molmed.2025.05.001",

language = "English",

volume = "31",

pages = "1021--1031",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd.",

number = "11",

}

Korkmaz, F, Gimenez-Roig, J, Sultana, F, Laurencin, V, Sen, F, Cullen, L, Sims, S, Pallapati, A , Rojekar, S, Burganova, G, Pevnev, G, Cheliadinova, U, Vasilyeva, D, Moldavski, O , Frolinger, T , Gumerova, A, Barak, O, Ryu, V , Lizneva, D, Ye, K, Schafer, A, Rosen, CJ, Yuen, T , Kim, SM & Zaidi, M 2025, 'Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease', Trends in Molecular Medicine, vol. 31, no. 11, pp. 1021-1031. https://doi.org/10.1016/j.molmed.2025.05.001

TY - JOUR

T1 - Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease

AU - Korkmaz, Funda

AU - Gimenez-Roig, Judit

AU - Sultana, Farhath

AU - Laurencin, Victoria

AU - Sen, Fasilet

AU - Cullen, Liam

AU - Sims, Steven

AU - Pallapati, Anusha

AU - Rojekar, Satish

AU - Burganova, Guzel

AU - Pevnev, Georgii

AU - Cheliadinova, Uliana

AU - Vasilyeva, Darya

AU - Moldavski, Ofer

AU - Frolinger, Tal

AU - Gumerova, Anisa

AU - Barak, Orly

AU - Ryu, Vitaly

AU - Lizneva, Daria

AU - Ye, Keqiang

AU - Schafer, Anne

AU - Rosen, Clifford J.

AU - Yuen, Tony

AU - Kim, Se Min

AU - Zaidi, Mone

PY - 2025/11

Y1 - 2025/11

N2 - Follicle-stimulating hormone (FSH), traditionally known for regulating gonadal development, maturation, and estrogen secretion, has now been implicated in regulating fat and bone metabolism and cognition. Preclinical evidence from genetic and pharmacological studies in rodent models, combined with human data from population-based observations, genetic studies, and a limited number of interventional trials, supports the notion of independent effects of FSH on the skeleton, fat, and brain. This evolving understanding of the nonreproductive roles of FSH presents potential therapeutic opportunities to mitigate age-related health challenges, which include osteoporosis, obesity, cardiovascular risk, and dementia. This review summarizes the current knowledge on the interplay between pituitary-derived FSH and peripheral and central tissues, as well as recent progress in therapeutic development.

AB - Follicle-stimulating hormone (FSH), traditionally known for regulating gonadal development, maturation, and estrogen secretion, has now been implicated in regulating fat and bone metabolism and cognition. Preclinical evidence from genetic and pharmacological studies in rodent models, combined with human data from population-based observations, genetic studies, and a limited number of interventional trials, supports the notion of independent effects of FSH on the skeleton, fat, and brain. This evolving understanding of the nonreproductive roles of FSH presents potential therapeutic opportunities to mitigate age-related health challenges, which include osteoporosis, obesity, cardiovascular risk, and dementia. This review summarizes the current knowledge on the interplay between pituitary-derived FSH and peripheral and central tissues, as well as recent progress in therapeutic development.

KW - FSH

KW - bone

KW - brain

KW - fat

KW - pituitary

UR - https://www.scopus.com/pages/publications/105007539628

U2 - 10.1016/j.molmed.2025.05.001

DO - 10.1016/j.molmed.2025.05.001

M3 - Review article

AN - SCOPUS:105007539628

SN - 1471-4914

VL - 31

SP - 1021

EP - 1031

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 11

ER -

Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this